| pubmed-article:18617654 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0007226 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0038454 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0360714 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0441471 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0201950 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C1550594 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0205345 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0428466 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C1548760 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C1547300 | lld:lifeskim |
| pubmed-article:18617654 | lifeskim:mentions | umls-concept:C0580822 | lld:lifeskim |
| pubmed-article:18617654 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18617654 | pubmed:dateCreated | 2008-8-26 | lld:pubmed |
| pubmed-article:18617654 | pubmed:abstractText | In SPARCL, treatment with atorvastatin 80 mg daily reduced stroke risk in patients with recent stroke or TIA and no known coronary heart disease by 16% versus placebo over 4.9 years of follow-up. The purpose of this secondary analysis was to determine whether men and women similarly benefited from randomization to statin treatment. | lld:pubmed |
| pubmed-article:18617654 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18617654 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18617654 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18617654 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18617654 | pubmed:issn | 1524-4628 | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:SillesenHenri... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:AmarencoPierr... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:GoldsteinLarr... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:HennericiMich... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:MessigMichael... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:WelchK... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:SPARCL... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:GilbertSteven... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:LamonteMarian... | lld:pubmed |
| pubmed-article:18617654 | pubmed:author | pubmed-author:CallahanAlfre... | lld:pubmed |
| pubmed-article:18617654 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18617654 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:18617654 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18617654 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18617654 | pubmed:pagination | 2444-8 | lld:pubmed |
| pubmed-article:18617654 | pubmed:dateRevised | 2008-11-12 | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:meshHeading | pubmed-meshheading:18617654... | lld:pubmed |
| pubmed-article:18617654 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18617654 | pubmed:articleTitle | Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. | lld:pubmed |
| pubmed-article:18617654 | pubmed:affiliation | Duke University Medical Center, Durham, NC 27710, USA. golds004@mc.duke.edu | lld:pubmed |
| pubmed-article:18617654 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18617654 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18617654 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18617654 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18617654 | lld:pubmed |
